Login to Your Account

'Cabo' on Time for Exelixis, Fares Well; Wider Label Next?

By Randy Osborne
Staff Writer

Friday, November 30, 2012
As expected, Exelixis Inc. won the FDA's nod for cabozantinib, a therapy for medullary thyroid cancer (MTC) – a less common form of the disease, originating in parafollicular C cells – but bigger revenue potential lies ahead, if the compound passes muster in metastatic prostate cancer, where Phase III trials are under way.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription